What the internist should know about hereditary muscle channelopathies

Abstract Objectives: Non-dystrophic myotonia, periodic paralysis and, to a certain extent, myotonic dystrophies are rare hereditary skeletal muscle channelopathies, charactarized by myotonia or episodic muscle weakness. This review highlights the diagnostic challenges and treatment options. Results: Some of these rare skeletal muscle disorders are associated with a broad range of systemic and nonspecific muscle symptoms. Consequently, patients are often referred to the internist before seeing a neurologist. This article provides clinical clues to better diagnose an tackle these unique disorders. Conclusion: A increased knowledge will reduce the diagnostic delay, improve monitoring and treatment, and might even prevent potentially life-threatening conditions as seen in DM.

[1]  M. Hanna,et al.  Predominantly myalgic phenotype caused by the c.3466G>A p.A1156T mutation in SCN4A gene , 2017, Neurology.

[2]  L. Gutmann,et al.  Myotonic Dystrophy Type 1 Management and Therapeutics , 2016, Current Treatment Options in Neurology.

[3]  G. Bassez,et al.  Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification. , 2016, Revue neurologique.

[4]  G. Hillis,et al.  Structural and electrical cardiac abnormalities are prevalent in asymptomatic adults with myotonic dystrophy , 2016, Heart.

[5]  M. Cosottini,et al.  Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study , 2016, Orphanet Journal of Rare Diseases.

[6]  P. Brugada,et al.  SCN4A variants and Brugada syndrome: phenotypic and genotypic overlap between cardiac and skeletal muscle sodium channelopathies , 2015, European Journal of Human Genetics.

[7]  G. Meola,et al.  Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism , 2015, Journal of neuromuscular diseases.

[8]  G. Meola,et al.  Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms. , 2015, Biochimica et biophysica acta.

[9]  L. Kritharides,et al.  Myotonic dystrophy and the heart: A systematic review of evaluation and management. , 2015, International journal of cardiology.

[10]  J. Trivedi,et al.  Treatment and Management of Neuromuscular Channelopathies , 2014, Current Treatment Options in Neurology.

[11]  A. Vijayakumar,et al.  Thyrotoxic Periodic Paralysis: Clinical Challenges , 2014, Journal of thyroid research.

[12]  G. Meola,et al.  The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): long-term outcomes. , 2013, International journal of cardiology.

[13]  G. Meola,et al.  Vitamin D, parathyroid hormone and muscle impairment in myotonic dystrophies , 2013, Journal of the Neurological Sciences.

[14]  S. Peric,et al.  Cardiologic predictors of sudden death in patients with myotonic dystrophy type 1 , 2013, Journal of Clinical Neuroscience.

[15]  W. Chung,et al.  Severe dilated cardiomyopathy in a patient with myotonic dystrophy type 2 and homozygous repeat expansion in ZNF9. , 2012, Congestive heart failure.

[16]  P. Arlien‐Søborg,et al.  Endocrine function in 97 patients with myotonic dystrophy type 1 , 2012, Journal of Neurology.

[17]  M. Greene,et al.  Cancer risk among patients with myotonic muscular dystrophy. , 2011, JAMA.

[18]  W. Lissens,et al.  Late onset painful cold-aggravated myotonia: Three families with SCN4A L1436P mutation , 2011, Neuromuscular Disorders.

[19]  R. Tawil,et al.  Management and treatment of Andersen-Tawil syndrome (ATS) , 2007, Neurotherapeutics.

[20]  Changyu Shen,et al.  Increased mortality with left ventricular systolic dysfunction and heart failure in adults with myotonic dystrophy type 1. , 2010, American heart journal.

[21]  M. Hanna,et al.  Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis. , 2010, Current opinion in neurology.

[22]  R. Griggs,et al.  Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias , 2009, Current opinion in neurology.

[23]  A. Lazarus,et al.  Left ventricular dysfunction and cardiac arrhythmias are frequent in type 2 myotonic dystrophy: A case control study , 2009, Neuromuscular Disorders.

[24]  P. Hannonen,et al.  Myotonic dystrophy type 2 found in two of sixty-three persons diagnosed as having fibromyalgia. , 2008, Arthritis and rheumatism.

[25]  B. Engelen,et al.  Gastrointestinal involvement is frequent in Myotonic Dystrophy type 2 , 2008, Neuromuscular Disorders.

[26]  D. Zipes,et al.  Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. , 2008, The New England journal of medicine.

[27]  J. Willer,et al.  Cold extends electromyography distinction between ion channel mutations causing myotonia , 2006, Annals of neurology.

[28]  B. Schoser,et al.  Myotonic dystrophies type 1 and 2: a summary on current aspects. , 2006, Seminars in pediatric neurology.

[29]  M. Bellini,et al.  Gastrointestinal manifestations in myotonic muscular dystrophy. , 2006, World journal of gastroenterology.

[30]  P. Schwartz,et al.  Electrocardiographic Features in Andersen-Tawil Syndrome Patients With KCNJ2 Mutations: Characteristic T-U–Wave Patterns Predict the KCNJ2 Genotype , 2005, Circulation.

[31]  C. Sommer,et al.  Musculoskeletal pain in patients with myotonic dystrophy type 2. , 2004, Archives of neurology.

[32]  J. Willer,et al.  Electromyography guides toward subgroups of mutations in muscle channelopathies , 2004, Annals of neurology.

[33]  Hubert Kwiecinski,et al.  Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). , 2002, The Journal of clinical investigation.

[34]  S. Subramony,et al.  Mutations in Kir2.1 Cause the Developmental and Episodic Electrical Phenotypes of Andersen's Syndrome , 2001, Cell.

[35]  M. Kiyosawa,et al.  RETINAL CHANGES IN MYOTONIC DYSTROPHY: Clinical and Follow‐up Evaluation , 1993, Retina.